Glycerophospholipids

Name
Glycerophospholipids
Accession Number
DBCAT001464
Description

Derivatives of phosphatidic acid in which the hydrophobic regions are composed of two fatty acids and a polar alcohol is joined to the C-3 position of glycerol through a phosphodiester bond. They are named according to their polar head groups, such as phosphatidylcholine and phosphatidylethanolamine.

Drugs
DrugDrug Description
Phosphatidyl serineA nutrient used in some supplement products.
LecithinFatty substances commonly found in nutritional supplements.
Choline alfoscerateA natural choline that is used to manage declining cognitive function associated with neurodegenerative and vascular diseases.
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamineNot Available
Platelet Activating FactorNot Available
sn-glycero-3-phosphoethanolamineNot Available
CadaverineCadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine.
PhosphatidylethanolamineNot Available
L-DilinoleoyllecithinNot Available
LucinactantIntended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
ETC-588Investigated for use/treatment in atherosclerosis, coronary artery disease, and vascular diseases.
Colfosceril palmitateA pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
DL-dimyristoylphosphatidylcholineDL-dimyristoylphosphatidylcholine is not an active pharmaceutical agent and has no indication.
DL-dimyristoylphosphatidylglycerolDL-dimyristoylphosphatidylglycerol is not an considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indications.
MifamurtideA muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection.
1,2-DistearoyllecithinNot Annotated
VB-201VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).
Iopofosine I-131Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
1,​2-​Dioleoyl-​sn-​glycero-​3-​phospho-​L-​serineNot Annotated
CHF5633CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a synthetic SP-B analogue.
Drugs & Drug Targets
DrugTargetType
Phosphatidyl serinePhosphatidylserine decarboxylase proenzymetarget
Phosphatidyl serineScavenger receptor class B member 1target
Phosphatidyl serineProtein kinase C alpha typetarget
Phosphatidyl serinePhosphatidylserine synthase 1target
Phosphatidyl serineDiacylglycerol kinase gammatarget
Phosphatidyl serineDiacylglycerol kinase deltatarget
Phosphatidyl serinePhosphatidylserine synthase 2target
Phosphatidyl serineSphingomyelin phosphodiesterase 4target
Phosphatidyl serineSphingomyelin phosphodiesterase 3target
Phosphatidyl serineProbable phospholipid-transporting ATPase IAtarget
Choline alfoscerateGanglioside GM2 activatortarget
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamineRhodopsintarget
Platelet Activating FactorGanglioside GM2 activatortarget
Platelet Activating FactorP-glycoprotein 1transporter
Platelet Activating FactorPlatelet-activating factor receptortarget
sn-glycero-3-phosphoethanolamineAnnexin A5target
Cadaverine2-C-methyl-D-erythritol 4-phosphate cytidylyltransferasetarget
PhosphatidylethanolamineEndothelial protein C receptortarget
PhosphatidylethanolamineBacteriorhodopsintarget
PhosphatidylethanolaminePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENtarget
L-DilinoleoyllecithinPhosphatidylcholine transfer proteintarget
MifamurtideToll-like receptor 4target
MifamurtideNucleotide-binding oligomerization domain-containing protein 2target